Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.525 USD | +8.37% | -0.40% | -40.14% |
Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.13% | 522M | |
+2.42% | 42.75B | |
+47.70% | 41.61B | |
+12.04% | 41.34B | |
-8.83% | 26.59B | |
+7.04% | 25.49B | |
-22.60% | 18.12B | |
+30.39% | 12.24B | |
-2.06% | 11.76B | |
+9.06% | 11B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study